AbbVie
ABBV
#26
Rank
HK$3.110 T
Marketcap
HK$1,760
Share price
-1.15%
Change (1 day)
31.91%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

Revenue for AbbVie (ABBV)

Revenue in 2025 (TTM): HK$464.88 Billion

According to AbbVie's latest financial reports the company's current revenue (TTM ) is HK$464.30 Billion. In 2024 the company made a revenue of HK$437.34 Billion an increase over the revenue in the year 2023 that were of HK$424.22 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for AbbVie from 2011 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) HK$464.88 B6.3%
2024 HK$437.34 B3.09%
2023 HK$424.22 B-6.47%
2022 HK$453.59 B3.51%
2021 HK$438.19 B23.41%
2020 HK$355.08 B37.06%
2019 HK$259.07 B1.01%
2018 HK$256.48 B16.35%
2017 HK$220.45 B10.88%
2016 HK$198.81 B12.21%
2015 HK$177.17 B14.44%
2014 HK$154.81 B6.26%
2013 HK$145.70 B2.27%
2012 HK$142.46 B5.15%
2011 HK$135.48 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Pfizer
PFE
HK$488.76 B 5.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$373.92 B-19.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$462.55 B-0.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$280.01 B-39.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
HK$226.42 B-51.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
HK$78.35 B-83.12%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
HK$329.69 B-28.99%๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
HK$452.49 B-2.54%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
HK$20.88 B-95.50%๐Ÿ‡บ๐Ÿ‡ธ USA